Aptevo Therapeutics Inc. (APVO)
APVO Stock Price Chart
Explore Aptevo Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze APVO price movements and trends.
APVO Company Profile
Discover essential business fundamentals and corporate details for Aptevo Therapeutics Inc. (APVO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Jul 2016
Employees
37.00
CEO
Jeffrey G. Lamothe
Description
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
APVO Financial Timeline
Browse a chronological timeline of Aptevo Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$6.02.
Earnings released on 13 May 2026
EPS came in at -$6.41 falling short of the estimated -$5.60 by -14.46%.
Earnings released on 20 Mar 2026
EPS came in at $1.68k surpassing the estimated -$8.09 by +20.92k%.
Stock split effective on 30 Dec 2025
Shares were split 1 : 18 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 6 Nov 2025
EPS came in at -$40.11 falling short of the estimated -$37.59 by -6.70%.
Earnings released on 11 Aug 2025
EPS came in at -$151.08 falling short of the estimated -$0.45 by -33.47k%.
Stock split effective on 27 May 2025
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 May 2025
EPS came in at -$1.58k falling short of the estimated -$1.51k by -4.28%.
Earnings released on 4 Mar 2025
EPS came in at -$82.37 falling short of the estimated -$7.75 by -962.84%.
Stock split effective on 4 Dec 2024
Shares were split 1 : 37 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 Nov 2024
EPS came in at -$6.26k surpassing the estimated -$7.43k by +15.79%.
Earnings released on 8 Aug 2024
EPS came in at -$21.77k surpassing the estimated -$25.15k by +13.47%.
Earnings released on 8 May 2024
EPS came in at -$129.68k surpassing the estimated -$183.77k by +29.43%.
Stock split effective on 6 Mar 2024
Shares were split 1 : 44 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 5 Mar 2024
EPS came in at -$6.16 surpassing the estimated -$18.04 by +65.85%.
Earnings released on 14 Nov 2023
EPS came in at -$287.07k surpassing the estimated -$413.38k by +30.56%.
Earnings released on 10 Aug 2023
EPS came in at -$706.20k falling short of the estimated -$643.04k by -9.82%.
Earnings released on 11 May 2023
EPS came in at $149.28k surpassing the estimated -$683.23k by +121.85%.
Earnings released on 30 Mar 2023
EPS came in at -$0.95 surpassing the estimated -$1.53 by +37.91%.
Earnings released on 10 Nov 2022
EPS came in at -$878.44k surpassing the estimated -$941.59k by +6.71%.
Earnings released on 11 Aug 2022
EPS came in at -$1.07m falling short of the estimated -$763.61k by -39.85%.
Earnings released on 12 May 2022
EPS came in at -$912.89k falling short of the estimated -$660.26k by -38.26%, while revenue for the quarter reached $3.11m , missing expectations by -16.96%.
Earnings released on 24 Mar 2022
EPS came in at -$1.27 surpassing the estimated -$1.29 by +1.55%, while revenue for the quarter reached $3.67m , beating expectations by +7.79%.
Earnings released on 12 Nov 2021
EPS came in at -$832.51k surpassing the estimated -$849.73k by +2.03%, while revenue for the quarter reached $3.10m , missing expectations by -1.99%.
Earnings released on 12 Aug 2021
EPS came in at -$1.02m surpassing the estimated -$1.12m by +8.72%, while revenue for the quarter reached $3.11m , beating expectations by +245.56%.
APVO Stock Performance
Access detailed APVO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
